1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline, clinical course, and work-up among patients with and without RCVS
VariableRCVS (n = 9)No RCVS (n = 17)Pa
Age (mean) (yr)44.955.7.06
Women (%)8 (88.9)10 (58.8).19
Race
 White (%)8 (88.9)12 (70.6).39
 African American (%)1 (11.1)2 (11.8)
 Other (%)0 (0)3 (17.7)
Medical history
 Migraine (%)4 (44.4)0 (0).008
 Depression/anxiety (%)8 (88.9)3 (17.6).001
 Hypertension (%)2 (22.2)14 (82.4).009
 Trigger/associated condition7 (77.8)2 (11.8).002
Vasoconstrictive drugs
 SSRI (%)6 (66.7)1 (5.9).002
 Illicit drugs (%)0 (0)1 (5.9).65
 Postpartum (%)2 (22.2)0 (0).11
Clinical presentation
 Thunderclap headache (%)5 (55.6)1 (5.9).01
 Other headaches (%)2 (22.2)5 (29.4).54
Focal neurologic signs
 Hemiparesis/aphasia (%)5 (55.6)10 (58.8).99
 Visual symptoms (%)3 (33.3)1 (5.9).10
 Seizures (%)2 (22.0)1 (5.9).27
Diagnostic work-up
 ESR (mean) (mm/h)22.543.9.31
 CRP (mean) (mg/L)3.01.9.61
 Normal CSFb (%)2/5 (40.0)4/9 (44.4).99
 Brain biopsy (%)1 (11.1)1 (5.9).58
Abnormal neuroimaging findings (%)
 Infarct (%)3 (33.3)13 (76.5).046
 Multiple (%)2/3 (66.7)12/13 (92.3).35
 Borderzone territory (%)2/3 (66.7)1/13 (7.7).08
 IPH (%)0 (0)4 (23.5).26
 SAH in convexity (%)5 (55.6)2 (11.8).03
CTA/MRA with vasculopathy
 CTA [n = 14]c (%)2/5 (40)5/9 (55.6).99
 MRA [n = 16]c (%)2/6 (33.3)10/10 (100).008
 Patients with intracranial vasculopathy on DSA not detected by CTA and/or MRA (n = 26) (%)6/9 (66.7)3/17 (17.6).028
 RCVS-2 score  of ≥ 55 (55.6)1 (5.9).01
  • Note:—CRP indicates C-reactive protein; ESR, erythrocyte sedimentation rate; IPH, intraparenchymal hemorrhage; SSRI, selective serotonin reuptake inhibitor.
  • ↵a P value calculated using a t test, χ2 test, or Fisher test as appropriate.
  • ↵b Normal CSF if <5 cells and <50 mg/dL.
  • ↵c Number of examinations performed including both groups.